Antiarrhythmic drugs of class Ic in cardiology practice

Treatment of cardiac arrhythmias has consistently attracted the interest of researchers and practicing physicians. Class Ic antiarrhythmic drugs (AADs) have been the most discussed in recent decades due to conflicting research results. The objective of this review is to analyze the efficacy and safety of class Ic AADs available in the Russian Federation: lappaconitine hydrobromide, prolonged-release lappaconitine hydrobromide, propafenone, flecainide, and diethylaminopropionylethoxycarbonylaminophenothiazine. The pharmacological features (pharmacokinetics, pharmacodynamics), electrophysiological effects of class Ic AADs, and data on their efficacy in supraventricular and ventricular cardiac arrhythmias, which served as the basis for clinical recommendations, are presented. The safety, adverse events, limitations, and contraindications for the use of class Ic AADs, as well as the possibilities of individualizing therapy when using them, are discussed.